Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 122

1.

Potential Use of Desmopressin During Hepatic Resection for Colorectal Liver Metastases.

Garona J, Sobol NT, Solernó LM, Alonso DF.

J Surg Res. 2019 May;237:1-2. doi: 10.1016/j.jss.2018.12.010. Epub 2019 Jan 9. No abstract available.

PMID:
30694785
2.

In vitro and in vivo evaluation of desmopressin-loaded poly(D,L-lactic-co-glycolic acid) nanoparticles for its potential use in cancer treatment.

Chevalier MT, Garona J, Sobol NT, Farina HG, Alonso DF, Álvarez VA.

Nanomedicine (Lond). 2018 Nov;13(22):2835-2849. doi: 10.2217/nnm-2018-0065. Epub 2018 Nov 15.

PMID:
30430901
3.

Aberrant O-glycosylation modulates aggressiveness in neuroblastoma.

Cuello HA, Segatori VI, Albertó M, Gulino CA, Aschero R, Camarero S, Mutti LG, Madauss K, Alonso DF, Lubieniecki F, Gabri MR.

Oncotarget. 2018 Sep 25;9(75):34176-34188. doi: 10.18632/oncotarget.26169. eCollection 2018 Sep 25.

4.

Minimal disseminated disease evaluation and outcome in trilateral retinoblastoma.

Torbidoni AV, Sampor C, Laurent VE, Aschero R, Iyer S, Rossi J, Alderete D, Alonso DF, Szijan I, Chantada GL.

Br J Ophthalmol. 2018 Nov;102(11):1597-1601. doi: 10.1136/bjophthalmol-2018-312263. Epub 2018 Aug 27.

PMID:
30150278
5.

Antibody-dependent cell-mediated cytotoxicity induced by active immunotherapy based on racotumomab in non-small cell lung cancer patients.

Segatori VI, Cuello HA, Gulino CA, Albertó M, Venier C, Guthmann MD, Demarco IA, Alonso DF, Gabri MR.

Cancer Immunol Immunother. 2018 Aug;67(8):1285-1296. doi: 10.1007/s00262-018-2188-y. Epub 2018 Jun 23.

PMID:
29936534
6.

Preclinical Efficacy of [V4 Q5 ]dDAVP, a Second Generation Vasopressin Analog, on Metastatic Spread and Tumor-Associated Angiogenesis in Colorectal Cancer.

Garona J, Sobol NT, Pifano M, Segatori VI, Gomez DE, Ripoll GV, Alonso DF.

Cancer Res Treat. 2019 Apr;51(2):438-450. doi: 10.4143/crt.2018.040. Epub 2018 Jun 1.

7.

Search of vasopressin analogs with antiproliferative activity on small-cell lung cancer: drug design based on two different approaches.

Pifano M, Garona J, Sobol NT, Albertó M, Alonso DF, Ripoll GV.

Future Med Chem. 2018 Apr 1;10(8):879-894. doi: 10.4155/fmc-2017-0178. Epub 2018 Mar 28.

PMID:
29589487
8.

Relevance of small GTPase Rac1 pathway in drug and radio-resistance mechanisms: Opportunities in cancer therapeutics.

Cardama GA, Alonso DF, Gonzalez N, Maggio J, Gomez DE, Rolfo C, Menna PL.

Crit Rev Oncol Hematol. 2018 Apr;124:29-36. doi: 10.1016/j.critrevonc.2018.01.012. Epub 2018 Feb 4. Review.

PMID:
29548483
9.

Cigarette smoking significantly alters sperm DNA methylation patterns.

Jenkins TG, James ER, Alonso DF, Hoidal JR, Murphy PJ, Hotaling JM, Cairns BR, Carrell DT, Aston KI.

Andrology. 2017 Nov;5(6):1089-1099. doi: 10.1111/andr.12416. Epub 2017 Sep 26.

10.

Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy in Colorectal Cancer: Potential use of Perioperative Desmopressin to Reduce Allogenic Blood Transfusion Rates.

Garona J, Sobol NT, Alonso DF.

J Gastrointest Surg. 2017 Nov;21(11):1971-1973. doi: 10.1007/s11605-017-3551-6. Epub 2017 Aug 24. No abstract available.

PMID:
28840437
11.

Impact of Perioperative Blood Transfusion on Survival Among Women With Breast Cancer: Potential Benefits of Blood-Saving Agent Desmopressin Use During Surgery.

Garona J, Sobol NT, Alonso DF.

Am J Ther. 2018 Sep/Oct;25(5):e569-e570. doi: 10.1097/MJT.0000000000000647. No abstract available.

PMID:
28806181
12.

Peptide Agonists of Vasopressin V2 Receptor Reduce Expression of Neuroendocrine Markers and Tumor Growth in Human Lung and Prostate Tumor Cells.

Pifano M, Garona J, Capobianco CS, Gonzalez N, Alonso DF, Ripoll GV.

Front Oncol. 2017 Jan 30;7:11. doi: 10.3389/fonc.2017.00011. eCollection 2017.

13.

Pharmacological inhibition of Rac1-PAK1 axis restores tamoxifen sensitivity in human resistant breast cancer cells.

Gonzalez N, Cardama GA, Comin MJ, Segatori VI, Pifano M, Alonso DF, Gomez DE, Menna PL.

Cell Signal. 2017 Jan;30:154-161. doi: 10.1016/j.cellsig.2016.12.002. Epub 2016 Dec 7.

PMID:
27939839
14.

Minimal Disseminated Disease in Nonmetastatic Retinoblastoma With High-Risk Pathologic Features and Association With Disease-Free Survival.

Laurent VE, Torbidoni AV, Sampor C, Ottaviani D, Vazquez V, Gabri MR, Garcia de Davila MT, Ramirez-Ortiz MA, Alonso CN, Rossi J, Alonso DF, Chantada GL.

JAMA Ophthalmol. 2016 Dec 1;134(12):1374-1379. doi: 10.1001/jamaophthalmol.2016.4158.

PMID:
27787537
15.

Urokinase Exerts Antimetastatic Effects by Dissociating Clusters of Circulating Tumor Cells-Letter.

Garona J, Alonso DF.

Cancer Res. 2016 Aug 15;76(16):4908. doi: 10.1158/0008-5472.CAN-16-0119. No abstract available.

16.

Perioperative biology in primary breast cancer: selective targeting of vasopressin type 2 receptor using desmopressin as a novel therapeutic approach.

Garona J, Alonso DF.

Breast Cancer Res Treat. 2016 Aug;158(3):597-9. doi: 10.1007/s10549-016-3899-4. Epub 2016 Jul 8. No abstract available.

PMID:
27393620
17.

CIGB-300, an anti-CK2 peptide, inhibits angiogenesis, tumor cell invasion and metastasis in lung cancer models.

Benavent Acero F, Capobianco CS, Garona J, Cirigliano SM, Perera Y, Urtreger AJ, Perea SE, Alonso DF, Farina HG.

Lung Cancer. 2017 May;107:14-21. doi: 10.1016/j.lungcan.2016.05.026. Epub 2016 Jun 1.

PMID:
27319334
18.

Addition of vasopressin synthetic analogue [V(4)Q(5)]dDAVP to standard chemotherapy enhances tumour growth inhibition and impairs metastatic spread in aggressive breast tumour models.

Garona J, Pifano M, Pastrian MB, Gomez DE, Ripoll GV, Alonso DF.

Clin Exp Metastasis. 2016 Aug;33(6):589-600. doi: 10.1007/s10585-016-9799-5. Epub 2016 May 5.

PMID:
27146156
19.

Comparability of Antibody-Mediated Cell Killing Activity Between a Proposed Biosimilar RTXM83 and the Originator Rituximab.

Cuello HA, Segatori VI, Alberto M, Pesce A, Alonso DF, Gabri MR.

BioDrugs. 2016 Jun;30(3):225-31. doi: 10.1007/s40259-016-0171-8.

PMID:
27053342
20.

Racotumomab for treating lung cancer and pediatric refractory malignancies.

Gabri MR, Cacciavillano W, Chantada GL, Alonso DF.

Expert Opin Biol Ther. 2016;16(4):573-8. doi: 10.1517/14712598.2016.1157579. Review.

PMID:
26903265
21.

Cirrhosis, von Willebrand Factor (vWF) and the Low Incidence of Metastatic Malignancy in Injured Liver.

Alonso DF.

Eurasian J Med. 2015 Oct;47(3):229-30. doi: 10.5152/eurasianjmed.2015.53. No abstract available.

22.

RAC3 more than a nuclear receptor coactivator: a key inhibitor of senescence that is downregulated in aging.

Fernández Larrosa PN, Ruíz Grecco M, Mengual Gómez D, Alvarado CV, Panelo LC, Rubio MF, Alonso DF, Gómez DE, Costas MA.

Cell Death Dis. 2015 Oct 15;6:e1902. doi: 10.1038/cddis.2015.218.

23.

A phase II dose-escalation trial of perioperative desmopressin (1-desamino-8-d-arginine vasopressin) in breast cancer patients.

Weinberg RS, Grecco MO, Ferro GS, Seigelshifer DJ, Perroni NV, Terrier FJ, Sánchez-Luceros A, Maronna E, Sánchez-Marull R, Frahm I, Guthmann MD, Di Leo D, Spitzer E, Ciccia GN, Garona J, Pifano M, Torbidoni AV, Gomez DE, Ripoll GV, Gomez RE, Demarco IA, Alonso DF.

Springerplus. 2015 Aug 19;4:428. doi: 10.1186/s40064-015-1217-y. eCollection 2015.

24.

A Phase I Study of the Anti-Idiotype Vaccine Racotumomab in Neuroblastoma and Other Pediatric Refractory Malignancies.

Cacciavillano W, Sampor C, Venier C, Gabri MR, de Dávila MT, Galluzzo ML, Guthmann MD, Fainboim L, Alonso DF, Chantada GL.

Pediatr Blood Cancer. 2015 Dec;62(12):2120-4. doi: 10.1002/pbc.25631. Epub 2015 Jul 7.

PMID:
26154941
25.

Association of Cone-Rod Homeobox Transcription Factor Messenger RNA With Pediatric Metastatic Retinoblastoma.

Torbidoni AV, Laurent VE, Sampor C, Ottaviani D, Vazquez V, Gabri MR, Rossi J, de Dávila MT, Alonso C, Alonso DF, Chantada GL.

JAMA Ophthalmol. 2015 Jul;133(7):805-12. doi: 10.1001/jamaophthalmol.2015.0900.

PMID:
25928893
26.

Optimizing CIGB-300 intralesional delivery in locally advanced cervical cancer.

Sarduy MR, García I, Coca MA, Perera A, Torres LA, Valenzuela CM, Baladrón I, Solares M, Reyes V, Hernández I, Perera Y, Martínez YM, Molina L, González YM, Ancízar JA, Prats A, González L, Casacó CA, Acevedo BE, López-Saura PA, Alonso DF, Gómez R, Perea-Rodríguez SE; CERVIFARM-300-II Study Group.

Br J Cancer. 2015 May 12;112(10):1636-43. doi: 10.1038/bjc.2015.137. Epub 2015 Apr 16.

27.

The novel desmopressin analogue [V4Q5]dDAVP inhibits angiogenesis, tumour growth and metastases in vasopressin type 2 receptor-expressing breast cancer models.

Garona J, Pifano M, Orlando UD, Pastrian MB, Iannucci NB, Ortega HH, Podesta EJ, Gomez DE, Ripoll GV, Alonso DF.

Int J Oncol. 2015;46(6):2335-45. doi: 10.3892/ijo.2015.2952. Epub 2015 Apr 3.

28.

Proapoptotic and antiinvasive activity of Rac1 small molecule inhibitors on malignant glioma cells.

Cardama GA, Gonzalez N, Ciarlantini M, Gandolfi Donadío L, Comin MJ, Alonso DF, Menna PL, Gomez DE.

Onco Targets Ther. 2014 Oct 30;7:2021-33. doi: 10.2147/OTT.S67998. eCollection 2014.

29.

Insight into the effect of the vasopressin analog desmopressin on lung colonization by mammary carcinoma cells in BALB/c mice.

Garona J, Pifano M, Scursoni AM, Gomez DE, Alonso DF, Ripoll GV.

Anticancer Res. 2014 Sep;34(9):4761-5.

PMID:
25202055
30.

Mechanisms of cellular uptake, intracellular transportation, and degradation of CIGB-300, a Tat-conjugated peptide, in tumor cell lines.

Benavent Acero FR, Perera Negrin Y, Alonso DF, Perea SE, Gomez DE, Farina HG.

Mol Pharm. 2014 Jun 2;11(6):1798-807. doi: 10.1021/mp4006062. Epub 2014 Apr 28.

PMID:
24773585
31.

Structure-activity relationship of 1-desamino-8-D-arginine vasopressin as an antiproliferative agent on human vasopressin V2 receptor-expressing cancer cells.

Pastrian MB, Guzmán F, Garona J, Pifano M, Ripoll GV, Cascone O, Ciccia GN, Albericio F, Gómez DE, Alonso DF, Iannucci NB.

Mol Med Rep. 2014 Jun;9(6):2568-72. doi: 10.3892/mmr.2014.2140. Epub 2014 Apr 11.

PMID:
24737067
32.

Reduction of tumor angiogenesis induced by desmopressin in a breast cancer model.

Ripoll GV, Garona J, Pifano M, Farina HG, Gomez DE, Alonso DF.

Breast Cancer Res Treat. 2013 Nov;142(1):9-18.

33.

Preclinical development of novel Rac1-GEF signaling inhibitors using a rational design approach in highly aggressive breast cancer cell lines.

Cardama GA, Comin MJ, Hornos L, Gonzalez N, Defelipe L, Turjanski AG, Alonso DF, Gomez DE, Menna PL.

Anticancer Agents Med Chem. 2014;14(6):840-51.

34.

Detection of minimally disseminated disease in the cerebrospinal fluid of children with high-risk retinoblastoma by reverse transcriptase-polymerase chain reaction for GD2 synthase mRNA.

Laurent VE, Sampor C, Solernou V, Rossi J, Gabri M, Eandi-Eberle S, de Davila MT, Alonso DF, Chantada GL.

Eur J Cancer. 2013 Sep;49(13):2892-9. doi: 10.1016/j.ejca.2013.04.021. Epub 2013 May 27.

PMID:
23721779
35.

Anti-idiotype antibodies in cancer treatment.

Gomez DE, Vázquez AM, Alonso DF, Macías A.

Front Oncol. 2013 Feb 26;3:37. doi: 10.3389/fonc.2013.00037. eCollection 2013. No abstract available.

36.

Anti-ganglioside antibodies induced in chickens by an alum-adsorbed anti-idiotype antibody targeting NeuGcGM3.

Guthmann MD, Venier C, Toledo D, Segatori VI, Alonso DF, Fainboim L, Vázquez AM, Ostrowski H.

Front Immunol. 2013 Jan 17;3:422. doi: 10.3389/fimmu.2012.00422. eCollection 2012.

37.

Implication of von Willebrand factor as a regulator of tumor cell metastasis: potential perioperative use of desmopressin and novel peptide analogs.

Ripoll GV, Alonso DF.

Acta Haematol. 2013;129(4):223-4. doi: 10.1159/000346071. Epub 2013 Jan 3. No abstract available.

PMID:
23295681
38.

Preclinical evaluation of racotumomab, an anti-idiotype monoclonal antibody to N-glycolyl-containing gangliosides, with or without chemotherapy in a mouse model of non-small cell lung cancer.

Segatori VI, Vazquez AM, Gomez DE, Gabri MR, Alonso DF.

Front Oncol. 2012 Nov 8;2:160. doi: 10.3389/fonc.2012.00160. eCollection 2012.

39.

Re: Effect of ADAM28 on carcinoma cell metastasis by cleavage of von Willebrand factor.

Alonso DF.

J Natl Cancer Inst. 2012 Dec 19;104(24):1917; author reply 1917-8. doi: 10.1093/jnci/djs459. Epub 2012 Nov 6. No abstract available.

PMID:
23132922
40.

Racotumomab: an anti-idiotype vaccine related to N-glycolyl-containing gangliosides - preclinical and clinical data.

Vázquez AM, Hernández AM, Macías A, Montero E, Gómez DE, Alonso DF, Gabri MR, Gómez RE.

Front Oncol. 2012 Oct 23;2:150. doi: 10.3389/fonc.2012.00150. eCollection 2012.

41.

AZT as a telomerase inhibitor.

Gomez DE, Armando RG, Alonso DF.

Front Oncol. 2012 Sep 6;2:113. doi: 10.3389/fonc.2012.00113. eCollection 2012.

42.

Telomere structure and telomerase in health and disease (review).

Gomez DE, Armando RG, Farina HG, Menna PL, Cerrudo CS, Ghiringhelli PD, Alonso DF.

Int J Oncol. 2012 Nov;41(5):1561-9. doi: 10.3892/ijo.2012.1611. Epub 2012 Aug 29. Review.

43.

The functional interaction between Acyl-CoA synthetase 4, 5-lipooxygenase and cyclooxygenase-2 controls tumor growth: a novel therapeutic target.

Orlando UD, Garona J, Ripoll GV, Maloberti PM, Solano ÁR, Avagnina A, Gomez DE, Alonso DF, Podestá EJ.

PLoS One. 2012;7(7):e40794. doi: 10.1371/journal.pone.0040794. Epub 2012 Jul 13.

44.

Antitumor protection by NGcGM3/VSSP vaccine against transfected B16 mouse melanoma cells overexpressing N-glycolylated gangliosides.

Segatori VI, Otero LL, Fernandez LE, Gomez DE, Alonso DF, Gabri MR.

In Vivo. 2012 Jul-Aug;26(4):609-17.

PMID:
22773575
45.

Cancer antigen prioritization: a road map to work in defining vaccines against specific targets. A point of view.

Gomez DE, Vázquez AM, Alonso DF.

Front Oncol. 2012 Jun 28;2:66. doi: 10.3389/fonc.2012.00066. eCollection 2012. No abstract available.

46.

Sensitivity of tumor cells towards CIGB-300 anticancer peptide relies on its nucleolar localization.

Perera Y, Costales HC, Diaz Y, Reyes O, Farina HG, Mendez L, Gómez RE, Acevedo BE, Gomez DE, Alonso DF, Perea SE.

J Pept Sci. 2012 Apr;18(4):215-23. doi: 10.1002/psc.1432. Epub 2012 Mar 8.

PMID:
22407768
47.

Antiproliferative effect of 1-deamino-8-D-arginine vasopressin analogs on human breast cancer cells.

Iannucci NB, Ripoll GV, Garona J, Cascone O, Ciccia GN, Gomez DE, Alonso DF.

Future Med Chem. 2011 Dec;3(16):1987-93. doi: 10.4155/fmc.11.152.

48.

Immunoreactivity of the 14F7 Mab Raised against N-Glycolyl GM3 Ganglioside in Epithelial Malignant Tumors from Digestive System.

Blanco R, Rengifo E, Cedeño M, Rengifo CE, Alonso DF, Carr A.

ISRN Gastroenterol. 2011;2011:645641. doi: 10.5402/2011/645641. Epub 2010 Dec 2.

49.

Detection of N-glycolyl GM3 ganglioside in neuroectodermal tumors by immunohistochemistry: an attractive vaccine target for aggressive pediatric cancer.

Scursoni AM, Galluzzo L, Camarero S, Lopez J, Lubieniecki F, Sampor C, Segatori VI, Gabri MR, Alonso DF, Chantada G, de Dávila MT.

Clin Dev Immunol. 2011;2011:245181. doi: 10.1155/2011/245181. Epub 2011 Sep 20.

50.

CIGB-300, a synthetic peptide-based drug that targets the CK2 phosphoaceptor domain. Translational and clinical research.

Perea SE, Baladron I, Garcia Y, Perera Y, Lopez A, Soriano JL, Batista N, Palau A, Hernández I, Farina H, Garcia I, Gonzalez L, Gil J, Rodriguez A, Solares M, Santana A, Cruz M, Lopez M, Valenzuela C, Reyes O, López-Saura PA, González CA, Diaz A, Castellanos L, Sanchez A, Betancourt L, Besada V, González LJ, Garay H, Gómez R, Gómez DE, Alonso DF, Perrin P, Renualt JY, Sigman H, Herrera L, Acevedo B.

Mol Cell Biochem. 2011 Oct;356(1-2):45-50. doi: 10.1007/s11010-011-0950-y. Epub 2011 Jul 7.

PMID:
21735096

Supplemental Content

Loading ...
Support Center